New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?

Sanjiv S. Agarwala, MD

Dr Sanjiv Agarwala talks about exciting new results presented at ASCO 2018 in melanoma, including the durability of anti–PD-1 therapy in providing 40% overall survival at 5 years, updates on adjuvant therapy showing superiority of anti–PD-1 over anti–CTLA-4, and new results in combining immunotherapies.

Related Videos

January 10, 2019

Changing the Conversation: Immunotherapy and Long-Term Survival

Dr Morganna Freeman discusses some of the ways immunotherapy has changed cancer care, including the expectation for long-term survival and how to treat patients in remission.

September 2, 2015

Maintenance Setting

Dixie-Lee Esseltine, MD and George Mulligan, PhD discuss the challenges in the current standards of care of patients with multiple myeloma in the maintenance setting.